- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06806163
기계 학습 예측 및 EHR 누지의 과다 복용 감소 (mPROVEN)
The goal of this cluster randomized clinical trial is to test a clinician-targeted behavioral nudge intervention in the Electronic Health Record (EHR) for patients who are identified by a machine-learning based risk prediction model as having an elevated risk for an opioid overdose.
The clinical trial will evaluate the effectiveness of providing a flag in the EHR to identify individuals at elevated risk with and without behavioral nudges/best practice alerts (BPAs) as compared to usual care by primary care clinicians.
The primary goals of the study are to improve opioid prescribing safety and reduce overdose risk.
연구 개요
상태
상세 설명
In response to the opioid overdose crisis, health systems have instituted multiple interventions to reduce patient risk, including decreasing unsafe opioid prescribing among high-risk patients and dispensing naloxone. However, these interventions face two key challenges. First, there are limited and poorly performing tools to identify who is truly at risk of overdose, leading to burdensome interventions targeting an overly broad population or missing key high-risk individuals. Second, even with more accurate identification of high-risk patients, highly effective strategies to change clinician behavior remain limited. Common cognitive biases may underlie clinicians' lack of response to risk factors for overdose.
This project aims to address both of these limitations by combining more accurate risk prediction tools to identify those at elevated risk of opioid overdose with novel "nudge" interventions based on principles of behavioral economics that have been shown to address cognitive biases and change prescribing behavior. The primary hypothesis is that high-risk patients in primary care practices randomized to the elevated-risk flag + nudge intervention will have safer prescribing compared to usual care.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15213
- University of Pittsburgh
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Received an opioid prescription within the past year
- Age 18 years or older at the time of the opioid prescription
- At least one visit to an internal medicine or family care practice within the past year
Exclusion Criteria:
- Diagnosis of malignant cancer within the past year
- Enrollment in hospice care
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 건강 서비스 연구
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Usual Care
Patients in the practices randomized to the Usual Care arm will receive standard care practice without change. |
Patients in the practices randomized to the Usual Care arm will receive standard care practice without change. |
|
실험적: EHR-Embedded Elevated-Risk Flag
An elevated-risk flag will be embedded in the EHR and prominently displayed in the chart during encounters for patients identified as having elevated-risk for opioid overdose. |
Clinicians seeing patients at elevated predicted risk will see a flag on the EHR 'storyboard' during in person or telephone encounters indicating the patient is at elevated predicted risk of opioid overdose. The clinician will have the option of including this information into their decision-making process when providing care. There will be no best practice alerts/behavioral nudges in this arm. |
|
실험적: EHR-Embedded Elevated-Risk Flag with Behavioral Nudges
An elevated-risk flag will be embedded in the EHR and prominently displayed in the chart during encounters for patients identified as having elevated-risk for opioid overdose. This flag will be combined with a set of best practice alerts/behavioral nudges that will trigger when certain conditions are met during encounters with elevated-risk patients. |
Clinicians seeing patients at elevated predicted risk for opioid overdose will see a flag on the EHR storyboard indicating that the patient is at elevated predicted risk. Clinicians will also receive up to 4 best practice alerts/behavioral nudges during an in-person or telephone primary care encounter with elevated risk patients when certain requirements are met: 1) if the patient does not have an active naloxone prescription on their medication list, the clinicians will receive an active choice alert during any medication ordering to encourage naloxone prescription; 2) if the patient's opioid dosage is >50 MME, OR they are ordered a new opioid prescription, OR they have an overlapping opioid and benzodiazepine prescription order, the clinicians will receive an accountable justification alert when the relevant order is entered.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Prescribing Practices Composite Score
기간: Assessed at 4 months following study enrollment (i.e., at 4 months after the first encounter in the study period. An encounter refers to the 1st primary care visit for a patient enrolled in the study.)
|
This outcome measures a composite of three prescribing practices associated with a reduced risk of opioid overdose. Each of the three is assigned a value of one point, with the composite score ranging from 0 to 3:
The composite score will be treated as a 3-point ordinal measure reflecting adherence to these prescribing practices. |
Assessed at 4 months following study enrollment (i.e., at 4 months after the first encounter in the study period. An encounter refers to the 1st primary care visit for a patient enrolled in the study.)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Prescribing Practices Composite Score--6 Month Measure
기간: Assessed at 6 months following study enrollment (i.e., at 6 months after the first encounter in the study period. An encounter refers to the 1st primary care visit for a patient enrolled in the study.)
|
This outcome measures a composite of three prescribing practices associated with a reduced risk of opioid overdose. Each of the three is assigned a value of one point, with the composite score ranging from 0 to 3: 1. Naloxone prescription: Evidence of a prescription for naloxone. 2. Opioid dosage < 50 morphine milligram equivalents (MME) per day: No prescriptions exceeding 50 MME/day during the measurement period. 3. No opioid and benzodiazepine overlap: No concurrent prescriptions for opioids and benzodiazepines. The composite score will be treated as a 3-point ordinal measure reflecting adherence to these prescribing practices. |
Assessed at 6 months following study enrollment (i.e., at 6 months after the first encounter in the study period. An encounter refers to the 1st primary care visit for a patient enrolled in the study.)
|
|
Active Naloxone Prescription
기간: Assessed at 4 & 6 months after study enrollment by reviewing data from 12 months preceding index date (i.e., at 4 & 6 months after enrollment). An active naloxone prescription is recorded if one exists at any point during the year before the index date.
|
The presence of an active naloxone prescription, determined by evidence of a naloxone order, a naloxone fill, or both. |
Assessed at 4 & 6 months after study enrollment by reviewing data from 12 months preceding index date (i.e., at 4 & 6 months after enrollment). An active naloxone prescription is recorded if one exists at any point during the year before the index date.
|
|
Average Daily Opioid Dosage > 50 MME
기간: Assessed at 4 and 6 months after study enrollment, based on the average daily MME calculated over the 7 days preceding the index date (i.e., 4 and 6 months after enrollment).
|
The average daily opioid dosage, calculated in morphine milligram equivalents (MME), is evaluated using prescription fills data as the primary source. If fills data are unavailable, prescription orders data will be used. This measure reflects whether the average daily MME exceeds 50 during the specified time period. |
Assessed at 4 and 6 months after study enrollment, based on the average daily MME calculated over the 7 days preceding the index date (i.e., 4 and 6 months after enrollment).
|
|
Overlapping Opioid Benzodiazepine Prescriptions
기간: Assessed at 4 and 6 months after study enrollment, based on overlap occurring on the index date (i.e., 4 and 6 months after enrollment) or within the 28 days preceding the index date.
|
This outcome evaluates overlapping opioid and benzodiazepine use, determined by the following criteria: (A) Active overlap on the index date: Both an opioid and a benzodiazepine prescription fill are active on the index date. (B) Historical overlap: At least one opioid and one benzodiazepine prescription order within the past 28 days. Overlap is defined as meeting any of the above. |
Assessed at 4 and 6 months after study enrollment, based on overlap occurring on the index date (i.e., 4 and 6 months after enrollment) or within the 28 days preceding the index date.
|
|
Overlapping Opioid Benzodiazepine Prescriptions Where Average Daily Opioid MME > 50
기간: Assessed at 4 and 6 months after study enrollment, based on overlap occurring on the index date (i.e., 4 and 6 months after enrollment) or within the 28 days preceding the index date.
|
This outcome evaluates the presence of overlapping opioid and benzodiazepine use where opioid MME is > 50, defined as above. |
Assessed at 4 and 6 months after study enrollment, based on overlap occurring on the index date (i.e., 4 and 6 months after enrollment) or within the 28 days preceding the index date.
|
|
Emergency Department or Inpatient Visits
기간: Assessed at 4 and 6 months after study enrollment, based on visits occurring within the 30 days prior to the index date (i.e., 4 and 6 months after enrollment).
|
This outcome measures the occurrence of any emergency department (ED) or inpatient visit during the specified time period. |
Assessed at 4 and 6 months after study enrollment, based on visits occurring within the 30 days prior to the index date (i.e., 4 and 6 months after enrollment).
|
|
Emergency Department or Inpatient Visits for Overdose
기간: Assessed at 4 and 6 months after study enrollment, based on visits occurring within the 30 days prior to the index date (i.e., 4 and 6 months after enrollment).
|
This outcome measures the occurrence of any emergency department (ED) or inpatient visit specifically attributed to an overdose during the specified time period. |
Assessed at 4 and 6 months after study enrollment, based on visits occurring within the 30 days prior to the index date (i.e., 4 and 6 months after enrollment).
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Walid F Gellad, MD, MPH, University of Pittsburgh Center for Pharmaceutical Policy and Prescribing
간행물 및 유용한 링크
일반 간행물
- Lo-Ciganic WH, Huang JL, Zhang HH, Weiss JC, Kwoh CK, Donohue JM, Gordon AJ, Cochran G, Malone DC, Kuza CC, Gellad WF. Using machine learning to predict risk of incident opioid use disorder among fee-for-service Medicare beneficiaries: A prognostic study. PLoS One. 2020 Jul 17;15(7):e0235981. doi: 10.1371/journal.pone.0235981. eCollection 2020.
- Lo-Ciganic WH, Donohue JM, Hulsey EG, Barnes S, Li Y, Kuza CC, Yang Q, Buchanich J, Huang JL, Mair C, Wilson DL, Gellad WF. Integrating human services and criminal justice data with claims data to predict risk of opioid overdose among Medicaid beneficiaries: A machine-learning approach. PLoS One. 2021 Mar 18;16(3):e0248360. doi: 10.1371/journal.pone.0248360. eCollection 2021.
- Lo-Ciganic WH, Donohue JM, Yang Q, Huang JL, Chang CY, Weiss JC, Guo J, Zhang HH, Cochran G, Gordon AJ, Malone DC, Kwoh CK, Wilson DL, Kuza CC, Gellad WF. Developing and validating a machine-learning algorithm to predict opioid overdose in Medicaid beneficiaries in two US states: a prognostic modelling study. Lancet Digit Health. 2022 Jun;4(6):e455-e465. doi: 10.1016/S2589-7500(22)00062-0.
- Guo J, Gellad WF, Yang Q, Weiss JC, Donohue JM, Cochran G, Gordon AJ, Malone DC, Kwoh CK, Kuza CC, Wilson DL, Lo-Ciganic WH. Changes in predicted opioid overdose risk over time in a state Medicaid program: a group-based trajectory modeling analysis. Addiction. 2022 Aug;117(8):2254-2263. doi: 10.1111/add.15878. Epub 2022 Apr 3.
- Hulsey E, Hershey TB, Parker LS, Kuza C, Fedro-Byrom S, Gellad WF. Overdose Risk Prediction Algorithms: The Need for a Comprehensive Legal Framework. Health Affairs Forefront. 2022 November 22. doi: 10.1377/forefront.20221118.549875.
- Gellad WF, Yang Q, Adamson KM, Kuza CC, Buchanich JM, Bolton AL, Murzynski SM, Goetz CT, Washington T, Lann MF, Chang CH, Suda KJ, Tang L. Development and validation of an overdose risk prediction tool using prescription drug monitoring program data. Drug Alcohol Depend. 2023 May 1;246:109856. doi: 10.1016/j.drugalcdep.2023.109856. Epub 2023 Mar 27.
- Nguyen K, Wilson DL, Diiulio J, Hall B, Militello L, Gellad WF, Harle CA, Lewis M, Schmidt S, Rosenberg EI, Nelson D, He X, Wu Y, Bian J, Staras SAS, Gordon AJ, Cochran J, Kuza C, Yang S, Lo-Ciganic W. Design and development of a machine-learning-driven opioid overdose risk prediction tool integrated in electronic health records in primary care settings. Bioelectron Med. 2024 Oct 18;10(1):24. doi: 10.1186/s42234-024-00156-3.
- Militello LG, Diiulio J, Wilson DL, Nguyen KA, Harle CA, Gellad W, Lo-Ciganic WH. Using human factors methods to mitigate bias in artificial intelligence-based clinical decision support. J Am Med Inform Assoc. 2025 Feb 1;32(2):398-403. doi: 10.1093/jamia/ocae291.
- Lo-Ciganic WH, Huang JL, Zhang HH, Weiss JC, Wu Y, Kwoh CK, Donohue JM, Cochran G, Gordon AJ, Malone DC, Kuza CC, Gellad WF. Evaluation of Machine-Learning Algorithms for Predicting Opioid Overdose Risk Among Medicare Beneficiaries With Opioid Prescriptions. JAMA Netw Open. 2019 Mar 1;2(3):e190968. doi: 10.1001/jamanetworkopen.2019.0968.
- Gellad WF, Chen YF, Park TW, Yang Q, Arnold JD, Kuza CC, Fedro-Byrom SN, Diiulio J, Militello LG, Whitlock M, Sadhu EM, Visweswaran S, Fine MJ, Abebe KZ, Suda KJ, Lo-Ciganic WH. Machine Learning Prediction and Reducing Overdoses With Electronic Health Record Nudges (mPROVEN) in the Primary Care Setting: Protocol for a Cluster Randomized Controlled Trial. JMIR Res Protoc. 2026 May 4;15:e94007. doi: 10.2196/94007.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- STUDY22040068
- R01DA044985-04 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .